Zenas BioPharma Reports $10 Million in Third-Quarter Revenue
Revenue was $10.0 million, compared with none a year earlier, after the company recognized a BMS development and regulatory milestone. EPS was a loss of $1.65.
Zenas BioPharma reported $10.0 million in revenue, compared with none a year earlier, as it recognized a BMS development and regulatory milestone. Net loss widened, driven by higher research and development and general and administrative expenses, milestone-related acquired IPR&D costs, and increas…